Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Conditions

• Myelofibrosis
• Myelodysplastic Syndrome
• Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome
• Myeloproliferative Neoplasm
• Relapsed or Refractory Primary Myelofibrosis
• Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
• ET (Essential Thrombocythemia)

Interventions

• DRUG: INCB057643
• DRUG: Ruxolitinib

Sponsor

Incyte Corporation